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To the Editor:
In our opinion, the article entitled “Analysis of the Presynaptic Signaling
Mechanisms Underlying the inhibition of LTP in Rat Dentate Gyrus by the
Tyrosine Kinase Inhibitor, Genistein,” by Casey et al. (2002), presents
weakly supported results that do not allow the interpretation suggested by
the authors. In this report, Casey and colleagues investigated a putative
presynaptic role for tyrosine kinases on long-term potentiation (LTP) in
perforant path-granule cell synapses. An increase in KCl-stimulated Ca2
influx and concomitant glutamate release was observed in synaptosomes
isolated from dentate gyrus that had sustained LTP after tetanic stimulation,
as compared with untetanized tissue. This was accompanied by an increase
in tyrosine phosphorylation of the 1-subunit of voltage-gated calcium
channels (VGCC) and of the phosphorylation of extracellular signal-regu-
lated kinase (ERK) in synaptosomes from tetanized dentate gyrus.
Increased protein synthesis and phosphorylation of the transcription
factor cAMP response element binding protein (CREB) were also ob-
served in the input cell bodies at the entorhinal cortex. To relate these
tetanus-induced events to tyrosine kinase activity, the broad-range in-
hibitor, genistein, was used. Intracerebroventricular injection of the
drug, before tetanic stimulation, inhibited LTP in vivo as well as LTP-
associated increases in glutamate release, Ca2 influx, phosphorylation
of the presynaptic proteins mentioned above, and protein synthesis.
Both genistein and PD098,059, an inhibitor of the kinase that activates
ERK (MEK), directly applied to untetanized synaptosomes, also inhib-
ited the release of KCl-stimulated Ca2 influx and glutamate. Based on
these results, the authors concluded that tyrosine phosphorylation of
certain presynaptic proteins modulates glutamate release, thereby con-
tributing to the expression of LTP.
We believe that the authors cannot draw this conclusion based on the data
presented. The conclusions of this study that introduce novelty, i.e., a role for
tyrosine kinases in LTP through a presynaptic action, are based solely on the use
of genistein. No attempt to prove the specificity of this drug wasmade, by using
inactive analogues or alternative tyrosine kinase inhibitors.
This is particularly important, as several nonspecific effects
have been reported for genistein. This compound inhibits
voltage-sensitiveNa channels (Paillart et al., 1997), cardiac
L-type Ca2 channels (Chiang et al., 1996), myocyte de-
layed-rectifier K currents (Washizuka et al., 1998),
GABAA and glycine receptors (Dunne et al., 1998; Huang
et al., 1999; Huang and Dillon, 2000) and activates cystic
fibrosis transmembrane conductance regulator Cl chan-
nels (French et al., 1997; Weinreich et al., 1997) in a ty-
rosine kinase-independent manner. Furthermore, we re-
cently showed that genistein inhibits KCl-induced Ca2
influx and glutamate release from hippocampal synapto-
somes in a nonspecific manner, since two other tyrosine
kinase inhibitors and two tyrosine phosphatase inhibitors
had no significant effect on the same events (Pereira et al.,
2003). A nonspecific inhibition of Ca2 influx by genistein
could account for the inhibition of glutamate release and the
decrease in tetanus-stimulated protein phosphorylation and
LTP, reported by Casey and colleagues. Therefore, it is not
possible to infer a role for tyrosine kinases in modulating
glutamate release and LTP, using genistein, as the authors
did.
Moreover, we recently reported that PD098,059 in-
hibits glutamate release from hippocampal synaptosomes
as a result of nonspecific inhibition of Ca2 influx, which
is not affected by U0126, another MEK inhibitor
(Pereira et al., 2002). Although we used higher concen-
trations (10–60 M), which caused nonetheless sub-
maximal ERK inhibition, it is not wise to conclude that
PD098,059 is acting through specificMEK inhibition in
this study. In fact, this report did not verify whether
PD098,059 actually inhibited ERK activity at such a low
concentration (2 M). Therefore, the conclusion drawn
by Casey and colleagues that ERK inhibition results in
reduced KCl-stimulated glutamate release from dentate
gyrus synaptosomes based solely on the use of
PD098,059, is again questionable.
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In conclusion, the report by Casey and colleagues is based on the
use of two pharmacological inhibitors that have nonspecific effects
and no attempt was made to verify their specificity. This lead the
authors to ambitious conclusions on the involvement of tyrosine
kinases on LTP in perforant path-granule cell synapses, that cannot
be inferred from the data presented in this article.
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